New River meets enrollment in phase 3 study of NRP104 for ADHD

By Elaine Rigoli

Tampa, Fla., Sept. 12 - New River Pharmaceuticals, Inc. said enrollment numbers have been met for the company's NRP104.303 study, which will examine the safety and efficacy of NRP104 as a treatment for attention-deficit/hyperactivity disorder in adult populations (ages 18-52).

The Radford, Va.-based specialty pharmaceutical company said it expects to complete the study in the fourth quarter of 2006, to announce top-line data from the study in the first quarter of 2007 and to file a supplemental New Drug Application for the adult indication in the second quarter of 2007.

The company also said the desired safety and efficacy endpoints were met in its NRP104.302 study of NRP104 in pediatric patients diagnosed with attention-deficit/hyperactivity disorder.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.